Articles tagged with Tumor Cells
Researchers have discovered a protein called focal adhesion kinase (FAK) that plays a crucial role in ovarian cancer cell growth. A network of signals generated by osteopontin and FAK controls spheroid growth, making it a potential target for new therapies.
Researchers discovered that switching off and then reactivating the Pax5 gene can reverse cancer in a common childhood leukemia model. Restoring its function enables normal blood cell development and cures the disease. The findings offer a promising new strategy for treating leukemia with fewer side effects.
Scientists create ultra-small nanoparticles that can bind to cancer cells using camel antibody fragments, potentially revolutionizing tumor detection. The particles successfully evade the human immune system and reach diseased cells under conditions similar to those in patients' bodies.
The study reveals that each glioblastoma tumor contains individual cells from multiple cancer sub-types, and that the distribution of these cells varies from tumor to tumor. This heterogeneity may contribute to drug resistance and disease recurrence, highlighting the need for personalized treatment approaches.
A Cornell research team has developed a new microfluidic device to isolate and study the most aggressive cancer cells. The device separates these cells from less aggressive ones, enabling researchers to analyze molecular changes that contribute to metastasis.
Researchers developed a new test that assesses metastatic risk by identifying specific cell types in tumor microenvironments. The test was more accurate than existing methods in predicting distant tumor spread and showed promise in tailoring therapy for breast cancer patients.
Scientists have discovered a potential new target for cancer immunotherapy, peptide antibodies that deplete immune-suppressing MDSCs without harming other vital cells. The treatment showed promising results in preclinical experiments, shrinking tumors and improving outcomes.
Researchers at Georgetown University Medical Center have developed a new technique to grow both normal and cancer cells indefinitely, transforming basic cancer research. This breakthrough allows for faster development of certain types of breast cancer in mice, with tumors behaving similarly to human breast cancer.
Researchers found that patients with tumor cells in their blood after surgery had a higher risk of relapse and poorer survival rates. The presence and count of tumor cells also predicted disease-free survival, with those having 5 or more CTCs at higher risk of recurrent disease.
A Phase I study of an experimental antibody produced at St. Jude Children's Research Hospital found tumors shrank or disappeared in some patients with advanced neuroblastoma, and disease progression was temporarily halted in 15 children.
A study led by Tufts University researchers reveals that SLUG transcription factor regulates stem cell function and determines breast cancer type, with potential implications for targeted therapies. The study found that SLUG-deficient mice exhibited defects in breast-cell differentiation and tumor formation.
Researchers at Johns Hopkins University discovered a novel method cancer cells use to migrate through the body by leveraging a propulsion system based on water and charged particles. The Osmotic Engine Model reveals how sodium-hydrogen ions, aquaporins, and water create a flow that propels cells forward.
Researchers have developed tiny, biodegradable nanoparticles that can carry DNA to brain cancer cells in mice, demonstrating potential for targeted treatment. The particles selectively induce death in cancer cells while leaving healthy cells intact, with the possibility of being given to patients during neurosurgery.
Researchers at Thomas Jefferson University found that a single cell type, T-helper cells, is actively suppressed in several experimental cancer vaccines. This discovery paves the way for methods to break suppression and improve cancer vaccine effectiveness.
Researchers pinpoint normal cell type that can give rise to invasive bladder cancers, explaining recurrence after therapy and potential therapeutic targets. Most bladder cancers arise from a corrupted lining with high probability of progression.
Researchers at Beth Israel Deaconess Medical Center have identified a key enzyme responsible for lactate production in cancer cells, which they inhibit to halt tumor growth and even cause regression. The study's findings offer promising results for new treatments targeting cancer metabolism.
A team of researchers identified four transcription factors that distinguish glioblastoma stem cells from more differentiated tumor cells. These factors were found to be active in 2-7% of human glioblastoma cells and could be targeted by new therapeutic approaches.
Researchers at UNC Lineberger Comprehensive Cancer Center found that cancer cells stiffen in response to mechanical force, opening gaps for immune cells to pass through. This discovery sheds new light on cancer development and metastasis, potentially leading to new therapies.
Researchers at Penn State College of Medicine found that breast cancer cell subpopulation cooperation can lead to increased tumor growth. The study discovered that two distinct subclones within mammary tumors relied on each other to expand, with one producing a protein called Wnt1 that promoted tumor growth.
Research discovers that tumor cells' reliance on glucose for energy is driven by a defective gene that fails to degrade glucose receptors, making them 'addicted' to sugar. The study offers new insights into the Warburg effect and potential treatment strategies.
Researchers at Lund University have developed a technique using magnetically controlled nanoparticles to selectively kill cancer cells while sparing healthy tissue. This method has the potential to revolutionize cancer treatment by reducing side effects associated with traditional therapies.
Researchers at Uppsala University have developed a paper filter that can remove virus particles with efficiency matching the best industrial filters. The filter uses 100% high purity cellulose nanofibers directly derived from nature, overcoming previous limitations in virus removal.
Researchers discovered that p53 acts to prevent cancer cell invasion by initiating a chain of events that ultimately prevents the formation of lamellipodia. This process involves the activation of a mitochondrial protease called Omi, which cleaves actin filaments and suppresses the activity of focal adhesion signaling protein p130Cas.
Scientists at Northwestern University have discovered that cancer cells rely on the FAS receptor and its binding component for survival, making them vulnerable to elimination. The team created a cancer cell completely devoid of CD95, which resulted in DNA damage and cell death, offering a promising new approach to kill cancer cells.
Researchers developed a comprehensive measurement method to visualize tumor cells and their interactions, providing insights into the heterogeneity of tumors. The new technique can simultaneously record 32 biomarkers and has the potential to pinpoint weak points in the control system, leading to more effective therapeutic approaches.
Researchers discovered that cancer cells hug capillaries and express specific proteins to survive in the brain. The tumor cells produce a protein acting like Velcro to attach themselves to blood vessels, allowing them to grow into new tumors.
Researchers have developed a cancer vaccine that utilizes the immune system to target and destroy tumor cells producing a specific protein. The vaccine, which involves genetically modified tumor cells producing IL-15 and its receptor, shows promise in slowing tumor growth and increasing survival rates in animal models.
Researchers evaluated the effectiveness and safety of an anti-FGF23 antibody in patients with X-linked hypophosphatemia, finding improved renal phosphate reabsorption and increased serum phosphate levels. Additionally, studies on natural killer cells suggest that targeting specific ligands may enhance cancer therapies by protecting tum...
Research reveals that Mdm2 suppresses tumor growth by inhibiting glycolysis through the degradation of PGAM. This process prevents cells from entering senescence and allows them to continue proliferating. The study provides new insights into how damaged cells respond to stress and offers potential avenues for cancer treatment.
Researchers created computer models using PySB framework to explore biochemical processes driving cancer growth. The models aim to identify what goes wrong in cancer cells' self-destruction signals, potentially leading to novel therapies.
Researchers at Karolinska Institutet have identified a new drug candidate, VLX600, that selectively kills dormant cancer cells in solid tumors by starving them. The drug works by inhibiting mitochondrial respiration, causing the cells to die from starvation. A clinical study is planned to take place this year.
Scientists use nanofibers to trick glioblastoma cells into moving away from inoperable brain locations and towards a 'tumor collector' gel containing a toxic drug. This technique may allow patients to live with slow-growing tumors, controlling their growth rather than eradicating the cancer.
A new study from Karolinska Institutet found that acidic tumor pH counteracts chloroquine's ability to inhibit autophagy in cancer cells. The results may explain the lack of efficacy of chloroquine in clinical studies, particularly in tumors with low oxygen and acidic pH.
Researchers at CNIO propose a new combined therapy to treat cancer by combining etoposide with compounds that interfere with the cell cycle, increasing specificity and improving the therapeutic window. This approach aims to reduce toxicity and increase effectiveness in treating tumour cells.
A study by Virginia Tech researchers reveals that brain tumor cells with diverse physical traits are safer due to chromosomal abnormalities. These abnormalities lead to cell diversity and survival of brain tumors.
A new study published in Cancer Research found that fragmented sleep accelerates cancer growth by altering the immune system's response to tumors. Well-rested mice had primarily M1-type tumor-associated macrophages, while sleep-fragmented mice had primarily M2-type macrophages that promoted tumor growth.
Researchers have developed a natural polysaccharide-based delivery system that enhances the targeting of DNA aptamers to vimentin in tumor cells, leading to increased cell death. The study uses arabinogalactan from the larch tree as a carrier and shows improved efficacy when combined with the aptamer drug.
Researchers developed a tool to predict which direction a breast cancer tumor is most likely to go and how it will respond to chemotherapy. The study's findings reveal general rules, including genetic diversity within tumors and the importance of analyzing individual cells.
Researchers found that focal adhesion kinase (FAK) plays a crucial role in enabling cancer cells to enter the bloodstream. FAK helps open endothelial cell layers, allowing tumor cells to metastasize.
Researchers found that macrophage populations actively phagocytose tumor cells following monoclonal antibody treatment. Optimized therapies may enhance macrophage recruitment and activity to improve removal of circulating tumor cells in cancer patients.
Researchers at Johns Hopkins Medicine have identified a small molecule compound called BMH-21 that targets and disrupts a key pathway in cancer cells, preventing their growth. By shutting down the RNA Polymerase pathway, BMH-21 prevents mutant cancer genes from communicating with cells and replicating.
The Damon Runyon Cancer Research Foundation has awarded over $2.8 million to 20 top young scientists for their innovative cancer research projects. The award provides independent funding to early career investigators to pursue novel ideas and aims to make paradigm-shifting breakthroughs in cancer prevention, diagnosis, and treatment.
The study identifies MAX as a tumor suppressor gene in aggressive lung cancer, which regulates the expression of BRG1 through direct recruitment to the MAX promoter. The depletion of BRG1 hinders cell growth and is synthetic lethal with MAX-deficient tumors.
Researchers found that activating p53 in normal cells induces Par-4 secretion, killing cancer cells. The paracrine effect targets tumor cells at distant sites, offering a new approach to treating tumors resistant to other treatments.
Engineered immune cells, called CARTmeso cells, have shown antitumor activity in two patients with advanced cancers that failed prior treatments. The temporary CARs are safe and trigger a response against the patient's own tumor, providing a new tool for solid cancer therapy.
A study published in Stem Cells reveals that bladder cancer originates from distinct stem cells for muscle-invasive and non-muscle invasive types. Genetic profiling identified specific gene signatures associated with each cell population, which predicted tumor stage and patient survival.
Senescent cells, a key mechanism of aging, have been identified by researchers. They found that satellite DNA unravels as cells enter senescence, leading to cell division inhibition. This discovery could lead to new treatments for cancer and age-related diseases like Progeria.
Research reveals that fusion between cancer cells and macrophages empowers cancer cells to spread, forming tumors more rapidly. The study's findings suggest a new mechanism by which cancer progression is driven.
Researchers at Johns Hopkins Medicine have identified a unique class of breast cancer cells that lead the invasion process into surrounding tissues. The team found that these 'leader cells' express a protein called K14, which is essential for their invasive behavior and may be a new target for therapy.
A team of University of Pennsylvania scientists has discovered a new mechanism of cancer spread by identifying the split personalities of a protein called Exo70. The research found that one form of Exo70 promotes cell movement and invasion, while the other helps maintain cellular structure and organization.
A new gene sequencing project identifies a family of drugs that enhance oxidative stress to kill rhabdomyosarcoma tumor cells and boost chemotherapy effectiveness. The study offers hope for treating this aggressive childhood cancer, particularly for patients with recurrent disease.
Researchers from Penn Medicine report promising results from a study of 59 leukemia patients treated with cell therapy, achieving high response rates and durable remissions. The treatment, known as CTL019, has shown long-term effectiveness in patients with both acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
A microchip-based device developed by MGH researchers may simplify the monitoring of patients' response to treatment for ovarian cancer. The team isolated and identified tumor cells from ascites, an accumulation of fluid in the abdomen that often occurs in abdominal cancers.
Researchers found that PKM2 controls mitosis, allowing cancer cells to safely divide and promoting brain tumor growth. Depleting PKM2 led to programmed cell death in tumor cells.
Researchers have discovered that tumour cells adopt the 'break-induced replication' (BIR) pathway to repair damaged replication forks, allowing for genome duplication. This pathway is common in cancer cells but rare in healthy cells, revealing a significant difference between these two types of cells.
Researchers found that two p53 isoforms, Δ133p53 and p53β, play a crucial role in regulating senescence. The study suggests that altering the ratio of these isoforms may be an effective therapeutic strategy for treating immunosenescence disorders.
A study published in the Journal of Clinical Investigation found that two p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. Additionally, a new gene therapy approach may not require immunosuppression, as regulatory T cells promote long-term expression.
Researchers at the University of Pennsylvania School of Medicine have developed a method to isolate and expand antitumor T cells from human tumor tissue. These T cells recognize specific proteins on cancer cells, making them potential candidates for targeted immunotherapy.
The university's premier biomedical instrument is expected to provide breakthroughs in treating animal and human health conditions, including cancer. The instrument uses thermal cell therapy and high-resolution imaging to target specific cells and tumors.
Mount Sinai researchers uncover the role of TGFβ2 in determining tumor cell behavior, revealing its potential as a biomarker for dormant cancer cells. The study confirms the 'seed and soil' theory of metastasis, suggesting that conditions within each organ influence tumor cell growth.